The GAVI vaccine alliance has stated that the first of nearly 100 million doses of US pharmaceutical company Johnson & Johnson's (J&J) (NYSE:JNJ) COVID-19 vaccine being donated by the European Union by year-end have begun arriving in African countries, Reuters news agency reported on Monday.
GAVI, which leads the COVAX vaccine sharing facility, said that this deal was negotiated as part of the bloc's overall pledge to share at least 500 million doses with low and lower-middle income countries by mid-2022.
Ursula von der Leyen, European Commission president, was quoted as saying: "The first doses have reached Niger, with more doses arriving in a number of countries this week."
The commission's statement also listed Guinea Conakry, Mauritania, the Central African Republic, Djibouti, Nigeria, Togo and the Republic of Congo.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older